Menopause, Bone Medication and Dental Implants: What to Discuss Before Treatment

Our companion article looks at what happens to bone biologically around menopause and how the jaw is assessed. This one deals with the practical conversation — the questions that actually change a treatment plan.

In practice, the single most important thing a patient in this group can bring to a consultation is an accurate and complete medication list. Not the medications she is currently taking for anything she considers dental, but everything, including tablets stopped several years ago and any injection given at a hospital. Antiresorptive medication in particular has implications for jaw surgery that persist well beyond the point at which the prescription ends, and a plan drawn up without that information is not a safe plan.

Which factor changes the plan most?

Medication history changes the plan most. Reduced systemic bone density is assessed locally with imaging and is usually manageable with adapted surgical technique. Antiresorptive medication is different: drugs such as bisphosphonates and denosumab alter bone turnover in a way that is directly relevant to how the jaw heals after surgery, and they are associated with a recognised though uncommon risk of impaired healing of exposed jawbone. The route of administration, the dose, the duration of treatment and the indication — osteoporosis versus oncology — all affect how that risk is judged. This is why the medication conversation, conducted with the prescribing doctor's input, comes before the surgical one.

Bisphosphonates and denosumab reduce bone resorption by inhibiting osteoclast activity. This is precisely why they work for osteoporosis — less resorption means less net bone loss and reduced fracture risk. The consequence is that overall bone turnover slows, and turnover is part of how bone repairs itself after injury.

The jaws remodel faster than most of the skeleton and are uniquely exposed to the oral environment through the gum. Where healing after extraction or surgery is impaired, an area of bone can remain exposed and fail to heal. This condition is well recognised, and it is the reason dental teams ask about these medications so persistently.

• Route. Oral medication taken for osteoporosis is associated with a considerably lower level of concern than intravenous administration in an oncology setting.

• Duration. Longer cumulative exposure is generally associated with greater concern.

• Indication. Doses used in cancer care are substantially higher than those used for osteoporosis.

• Other factors. Smoking, corticosteroid use, diabetes and poor oral hygiene compound the picture.

For most women taking oral medication for osteoporosis, dental treatment including implant placement is frequently possible, with the risk discussed openly as part of consent and with preventive measures in place. For patients on high-dose or intravenous regimens, elective jaw surgery is approached far more cautiously and alternatives are often preferred.

Never stop or alter this medication yourself, and do not accept a suggestion to stop it from anyone other than the prescribing doctor. Interrupting treatment carries its own fracture risk, and the benefit of doing so before dental surgery is not established.

Our companion article on osteoporosis medication and implant safety covers this topic in more depth.

HRT restores some of the oestrogen influence on bone turnover and is associated with preservation of bone density while it is taken. Its relationship with dental implant outcomes has been examined in a number of studies with mixed and not entirely consistent findings.

What can reasonably be said:

• HRT is prescribed for menopausal symptoms and bone health under medical supervision, not for dental reasons, and the decision belongs entirely with your doctor.

• It is not a prerequisite for implant treatment, and not taking it does not preclude it.

• It should be disclosed to your dental team as part of your medication history.

• It does not remove the need for local assessment of the implant site.

Where imaging shows insufficient ridge volume — which in this group is usually the result of long-standing tooth loss rather than hormonal change — several routes exist.

Socket grafting at the time of extraction. The most efficient intervention, because it limits the loss rather than trying to rebuild it later. See our article on alveolar ridge preservation.

Guided bone regeneration. Graft material and a barrier membrane used to rebuild width or height at a healed site.

Sinus elevation. Used in the upper back region where the sinus has expanded into the space left by lost teeth.

Avoiding grafting through design. Angled or shorter implants placed in available bone, or a design supported on fewer implants. Our article on angled placement where bone density is low covers this approach.

Grafting in a patient on antiresorptive medication requires the same careful risk discussion as any other jaw surgery.

• Full medication history, including anything stopped, and any hospital-administered injections.

• Bone health history — DEXA results, diagnosis of osteopenia or osteoporosis, fracture history.

• Written liaison with the prescribing doctor where antiresorptive medication is involved.

• Cone beam CT of the proposed site.

• Periodontal assessment. Gum health is a stronger determinant of implant outcomes than systemic bone density. See our gum disease treatment page.

• Assessment of dry mouth and decay risk, both common in this group.

• Discussion of alternatives, including dentures and conventional bridges, and of doing nothing.

The general implant pathway is described in our clinically-led guide to implants.

• Discuss calcium, vitamin D and weight-bearing exercise with your doctor.

• Do not smoke — this affects implant outcomes more than menopausal bone change does.

• Maintain thorough daily cleaning, including interdentally around any implant. Our article on water flossers for implants covers useful adjuncts.

• Attend professional maintenance at the interval advised. Our dental hygiene page explains what this involves.

• Manage dry mouth actively with water, sugar-free products and, where appropriate, saliva substitutes and high-fluoride toothpaste.

• Report any non-healing area, exposed bone, persistent pain or numbness in the jaw without delay.

The NHS provides general information about dental implants at nhs.uk.

Arrange an assessment if:

• You are considering implants and take or have taken medication for bone density.

• You have been diagnosed with osteopenia or osteoporosis.

• You need a tooth extracted and take antiresorptive medication — this needs planning, not a walk-in appointment.

• You have a non-healing socket, exposed bone or altered sensation in the jaw.

• Your gums bleed or have receded.

• You have developed dry mouth and new decay.

• You have been declined implant treatment and would like the reasoning explained with imaging.

• Medication history is the factor that most often changes the plan in this group.

• Antiresorptive drugs reduce bone turnover, which is relevant to how the jaw heals after surgery.

• Route, dose, duration and indication all affect how the risk is assessed.

• Oral osteoporosis medication is associated with a considerably lower level of concern than high-dose intravenous regimens.

• Medication must never be stopped without the prescribing doctor's instruction.

• HRT is a medical decision, is not required for implant treatment, and should be disclosed.

• Bone deficiency in this group usually reflects how long a tooth has been missing rather than hormonal change.

• Gum health and smoking status have a greater bearing on outcomes than menopausal status.

For women considering implants around menopause, the decisive information is rarely a bone density score. It is an accurate medication history, a clear picture of gum health, and three-dimensional imaging of the site in question. With those three things, a realistic plan can be made — and where implants are not the right answer, that becomes clear early rather than late.

If you would like to discuss your options, you can arrange an appointment with our team at 22 Wimpole St, London W1G 8GQ, or telephone 020 7183 0692.

Dental symptoms and treatment options should always be assessed individually during a clinical examination.

This article is for general educational information only and is not professional dental advice, diagnosis, or a treatment recommendation. Information here is general and cannot replace an in-person assessment by a qualified, GDC-registered dental professional. Symptoms, suitability, fees, timelines, and outcomes vary according to individual clinical circumstances. If you have pain, swelling, or other concerning symptoms, seek prompt professional dental care. Always request a written treatment plan and cost estimate before proceeding with treatment.

Written Date: 25 August 2026

Next Review Date: 25 August 2027